文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向实体瘤中的ATR通路:改善治疗效果的证据

Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.

作者信息

Mavroeidi Dimitra, Georganta Anastasia, Panagiotou Emmanouil, Syrigos Konstantinos, Souliotis Vassilis L

机构信息

Institute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece.

Third Department of Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 115 27 Athens, Greece.

出版信息

Int J Mol Sci. 2024 Feb 27;25(5):2767. doi: 10.3390/ijms25052767.


DOI:10.3390/ijms25052767
PMID:38474014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10932434/
Abstract

The DNA damage response (DDR) system is a complicated network of signaling pathways that detects and repairs DNA damage or induces apoptosis. Critical regulators of the DDR network include the DNA damage kinases ataxia telangiectasia mutated Rad3-related kinase (ATR) and ataxia-telangiectasia mutated (ATM). The ATR pathway coordinates processes such as replication stress response, stabilization of replication forks, cell cycle arrest, and DNA repair. ATR inhibition disrupts these functions, causing a reduction of DNA repair, accumulation of DNA damage, replication fork collapse, inappropriate mitotic entry, and mitotic catastrophe. Recent data have shown that the inhibition of ATR can lead to synthetic lethality in ATM-deficient malignancies. In addition, ATR inhibition plays a significant role in the activation of the immune system by increasing the tumor mutational burden and neoantigen load as well as by triggering the accumulation of cytosolic DNA and subsequently inducing the cGAS-STING pathway and the type I IFN response. Taken together, we review stimulating data showing that ATR kinase inhibition can alter the DDR network, the immune system, and their interplay and, therefore, potentially provide a novel strategy to improve the efficacy of antitumor therapy, using ATR inhibitors as monotherapy or in combination with genotoxic drugs and/or immunomodulators.

摘要

DNA损伤反应(DDR)系统是一个复杂的信号通路网络,可检测和修复DNA损伤或诱导细胞凋亡。DDR网络的关键调节因子包括DNA损伤激酶共济失调毛细血管扩张突变Rad3相关激酶(ATR)和共济失调毛细血管扩张突变(ATM)。ATR通路协调复制应激反应、复制叉稳定、细胞周期停滞和DNA修复等过程。ATR抑制会破坏这些功能,导致DNA修复减少、DNA损伤积累、复制叉崩溃、不适当的有丝分裂进入和有丝分裂灾难。最近的数据表明,ATR抑制可导致ATM缺陷型恶性肿瘤出现合成致死性。此外,ATR抑制通过增加肿瘤突变负担和新抗原负荷,以及触发胞质DNA积累,随后诱导cGAS-STING通路和I型干扰素反应,在免疫系统激活中发挥重要作用。综上所述,我们回顾了一些令人振奋的数据,这些数据表明,ATR激酶抑制可改变DDR网络、免疫系统及其相互作用,因此,有可能提供一种新的策略来提高抗肿瘤治疗的疗效,将ATR抑制剂作为单一疗法或与基因毒性药物和/或免疫调节剂联合使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ec/10932434/3829e90a9bde/ijms-25-02767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ec/10932434/d8bef454cac8/ijms-25-02767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ec/10932434/3829e90a9bde/ijms-25-02767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ec/10932434/d8bef454cac8/ijms-25-02767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ec/10932434/3829e90a9bde/ijms-25-02767-g002.jpg

相似文献

[1]
Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.

Int J Mol Sci. 2024-2-27

[2]
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Blood. 2015-11-12

[3]
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.

Cancer Res Treat. 2018-12-3

[4]
Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.

Cell Cycle. 2014

[5]
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.

Cancer Res. 2022-3-15

[6]
The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.

PLoS Pathog. 2016-2-11

[7]
Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.

Molecules. 2023-6-2

[8]
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

Oncotarget. 2015-12-29

[9]
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway.

Lancet. 2015-2-26

[10]
Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.

Drug Discov Today. 2023-8

引用本文的文献

[1]
ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment.

Int J Mol Sci. 2025-8-9

[2]
Elucidating DNA Damage-Dependent Immune System Activation.

Int J Mol Sci. 2025-6-18

[3]
Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage.

Cells. 2025-5-20

[4]
Discovery of novel serum peptide biomarkers for cholangiocarcinoma recurrence through MALDI-TOF MS and LC-MS/MS peptidome analysis.

Sci Rep. 2025-1-20

[5]
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

Gut. 2024-12-10

[6]
The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma.

Int J Mol Sci. 2024-6-26

本文引用的文献

[1]
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

J Clin Invest. 2024-1-16

[2]
ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.

Genes Dev. 2023-10-1

[3]
Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR.

Genes Dev. 2023-10-1

[4]
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.

Cancer. 2024-2-15

[5]
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).

Clin Cancer Res. 2023-12-1

[6]
DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy.

Cancers (Basel). 2023-3-6

[7]
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.

Cancer Commun (Lond). 2023-4

[8]
The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.

JCI Insight. 2023-2-22

[9]
Targeting the DNA damage response for cancer therapy.

Biochem Soc Trans. 2023-2-27

[10]
ATR Inhibition in Advanced Urothelial Carcinoma.

Clin Genitourin Cancer. 2023-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索